Eli Lilly & Co. (LLY) Granted FDA Priority Review Designation for Emgality (galcanezumab-gnlm) Injection for Preventive Treatment of Episodic Cluster Headache in Adults

March 5, 2019 6:48 AM
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)


Corporate News Management Comments

Next Articles